Scientists report promising activity of a novel drug that targets a key molecular driver of clear cell renal cell carcinoma (ccRCC) in patients with metastatic disease.
Dana-Farber Cancer Institute and Kronos Incorporated have joined forces to provide dedicated oncology care navigation services via a new benefit for Kronos employees and their beneficiaries.
A variety of existing drugs for treating conditions such as diabetes, inflammation, alcohol abuse, and arthritis in dogs can also kill cancer cells in the lab, according to a study by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
Dana-Farber Cancer Institute will establish the Riney Family Multiple Myeloma Initiative to help improve outcomes and accelerate understanding of the underlying biology for the most challenging types of myelomas, cancers that form in a type of white blood cell called a plasma cell.
Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer.
A new analysis shows that a donor stem cell transplant following treatment with an immune checkpoint inhibitor is generally safe and produces good outcomes for patients with Hodgkin lymphoma.
Results of studies on a novel agent to treat multiple myeloma and a combination therapy aimed at slowing the progression of a precursor myeloma condition are among reports being presented by Dana-Farber Cancer Institute investigators at the ASH Annual Meeting.
For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.
For older patients with acute myeloid leukemia (AML), the prospects for success of a stem cell transplant can often be predicted based on the particular set of genetic mutations within the tumor cells, investigators at Dana-Farber Cancer Institute and other research centers will report today at the ASH Annual Meeting.
Dana-Farber Cancer Institute researchers will present more than 40 research studies at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10 in Orlando, Fla.
Many non-white minority cancer survivors place importance on seeing doctors who share or understand their culture, but are less likely than non-Hispanic whites to be able to see such physicians, according to a new study from Dana-Farber Cancer Institute and University of Texas Southwestern. The study, which is one of the first nationally-representative studies to examine patient-reported preference for, access to, and quality of provider cultural competency among cancer survivors, published in JAMA Oncology.
A metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival, report scientists from Dana-Farber Cancer Institute.
In a study published online today by the journal Cancer, investigators at Dana-Farber Cancer Institute report that a single-session sleep education program for survivors can cure insomnia in many participants, and that those who don’t benefit from this approach are often helped by a more extensive, but still modest, three-session program.
A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Dana-Farber Cancer Institute.
Dana-Farber Cancer Institute has been awarded Magnet® status from the American Nurses Credentialing Center (ANCC) for the fourth consecutive time. This prestigious designation recognizes excellence in nursing practice and health care delivery and has been awarded to only 8% percent of hospitals in the United States.
Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a new study.
The discovery of the previously unknown mutation, reported in Nature Genetics by investigators from Dana-Farber/Brigham and Women’s Cancer Center, could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine if they carry the mutation, occurring in the gene known as RABL3.
Scientists at Dana-Farber Cancer Institute have demonstrated that an artificial intelligence tool can perform as well as human reviewers – and much more rapidly - in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer.
Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors – known as pNETs – that have dramatically different risks of recurrence following surgical treatment [or surgery]. The finding could yield predictive tests, ease anxiety in patients whose tumors are found to be unlikely to recur, while focusing vigilant follow-up monitoring on patients with pNETs having a higher rate of recurrence.
Researchers at Dana-Farber Cancer Institute and the VA Boston Healthcare System have uncovered a new vital sign for gauging survival and likelihood of having an unplanned hospitalization in older patients with blood cancers: the speed at which they can walk.In a study published today in the journal Blood, the researchers report that for every 0.
Enzalutamide, an oral androgen receptor inhibitor, can improve outcomes for men with metastatic hormone-sensitive prostate cancer (mHSPC), according to a large study presented by Christopher Sweeney, MBBS of Dana-Farber Cancer Institute's Lank Center for Genitourinary Oncology, during the American Society of Clinical Oncology (ASCO) Annual Meeting.
In patients with chronic lymphocytic leukemia, the rate of disease growth is apt to follow one of three trajectories: relentlessly upward, steadily level, or something in between, scientists at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, Massachusetts General Hospital, and the University of Washington report in a new study.
At a time when a growing number of men with prostate cancer considered “low risk” are opting for active surveillance or watchful waiting rather than immediate treatment with surgery or radiation, a new study reveals that black men are less likely than white men to adopt an active surveillance strategy for their disease.
Dana-Farber Cancer Institute researchers are presenting more than 70 research studies at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31st- June 4th. ASCO is the world’s largest clinical cancer research meeting, attracting more than 30,000 oncology professionals from around the world.
Researchers at Dana-Farber Cancer Institute have devised a risk model for determining whether patients with AWM have a low, intermediate, or high risk of developing symptomatic Waldenström macroglobulinemia
Results of a small clinical trial suggest that supplementing chemotherapy with high doses of vitamin D may benefit patients with metastatic colorectal cancer by delaying progression of the disease, say scientists from Dana-Farber Cancer Institute.
T-Mobile CEO is giving $4.5 million to support the Profile initiative at Dana-Farber Cancer Institute, one of the broadest and most comprehensive enterprise-level, patient-based cancer genomics projects in the world.
• Study uncovers extensive archive within adult cells of genes active at embryonic stage
• Memory can be accessed under certain conditions, making it possible to reactivate fetal genes
• Discovery may have major implications for regenerative medicine, cancer research
A new study shows that an innovative communication program developed by Ariadne Labs and tested at the Dana-Farber Cancer Institute resulted in more, earlier and better conversations between patients and their oncology clinicians, and led to significant reductions in emotional suffering for patients with advanced cancer.
Dana-Farber/Brigham and Women's Cancer Center announced the launch of the Young-Onset Colorectal Cancer Center. The center will provide expert, compassionate and cutting-edge care to young adult colon and rectal cancer patients with a focus on scientific discovery and research.
A combination of two drugs – one of them an immunotherapy agent – could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.
Many men with low-risk prostate cancer who most likely previously would have undergone immediate surgery or radiation are now adopting a more conservative “active surveillance” strategy, according to an analysis of a new federal database by scientists from Dana-Farber Cancer Institute.
By pairing a novel personalized cancer vaccine with a more established immunotherapy drug that is administered to patients in an innovative fashion, scientists at Dana-Farber Cancer Institute are testing a first-of-its-kind strategy aimed at improving outcomes for kidney cancer patients who are at high risk of recurrence following surgery.
In a report published in Nature, however, scientists at Dana-Farber Cancer Institute say they have shown that a personalized ‘neoantigen’ vaccine can spur a response against glioblastoma, with immune T-cells generated by the vaccine migrating into the brain tumor, creating a ‘hotter,’ inflamed environment around the cancer cells.
Black men diagnosed with prostate cancer classified as low risk may actually have a more aggressive form of the disease that is more likely to be fatal than in nonblack men placed in the same prognostic category, a new study suggests.
Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.
Improving outcomes for patients with myeloid cancers who undergo stem cell transplantation is a focus of several studies to be presented by Dana-Farber Cancer Institute scientists at the ASH Annual Meeting.
New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting.
A new option – a combination of a standard drug and the novel agent venetoclax – has been granted accelerated approval by the Food and Drug Administration for certain AML patients after a large, multicenter phase 1 clinical trial showed the combination had “promising efficacy” and was well tolerated in older AML patients.
• $1 million in initial funding to evaluate DNA repair inhibitors in pancreatic cancer
• Aim to accelerate pancreatic cancer research and improve patient outcomes for pancreatic cancer